SG11201407591PA - Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof - Google Patents
Process of making hydroxylated cyclopentapyrimidine compounds and salts thereofInfo
- Publication number
- SG11201407591PA SG11201407591PA SG11201407591PA SG11201407591PA SG11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA
- Authority
- SG
- Singapore
- Prior art keywords
- genentech
- california
- south san
- international
- san francisco
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648535P | 2012-05-17 | 2012-05-17 | |
| PCT/US2013/041695 WO2013173784A1 (fr) | 2012-05-17 | 2013-05-17 | Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407591PA true SG11201407591PA (en) | 2015-01-29 |
Family
ID=48534508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407591PA SG11201407591PA (en) | 2012-05-17 | 2013-05-17 | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9315471B2 (fr) |
| EP (1) | EP2850200A1 (fr) |
| JP (1) | JP6355625B2 (fr) |
| KR (1) | KR102123131B1 (fr) |
| CN (1) | CN104471070B (fr) |
| AU (1) | AU2013262521B2 (fr) |
| BR (1) | BR112014028573B1 (fr) |
| CA (1) | CA2873661C (fr) |
| HK (1) | HK1208500A1 (fr) |
| IL (1) | IL235699B (fr) |
| MA (1) | MA37647A1 (fr) |
| MX (1) | MX354373B (fr) |
| MY (1) | MY169029A (fr) |
| NZ (1) | NZ702950A (fr) |
| RU (1) | RU2642311C2 (fr) |
| SG (1) | SG11201407591PA (fr) |
| WO (1) | WO2013173784A1 (fr) |
| ZA (1) | ZA201409226B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014028585B1 (pt) | 2012-05-17 | 2020-12-22 | Genentech , Inc | processo para fabricação de aminoácidos, e seus intermediários |
| PT2858989T (pt) | 2012-05-17 | 2020-06-25 | Genentech Inc | Forma amorfa de um composto de pirimidinil-ciclopentano inibidor de akt, composições e métodos das mesmas |
| SG11201407613RA (en) | 2012-05-17 | 2015-01-29 | Array Biopharma Inc | Process for making hydroxylated cyclopentylpyrimidine compounds |
| PL2861582T3 (pl) | 2012-05-17 | 2016-11-30 | Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidynowych | |
| EP3656764B1 (fr) | 2013-11-15 | 2023-07-05 | F. Hoffmann-La Roche AG | Procédés de préparation pour dérivés de pyrmidinecyclopentane |
| AR102088A1 (es) * | 2014-09-26 | 2017-02-01 | Genentech Inc | Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina |
| JP6875501B2 (ja) | 2016-08-10 | 2021-05-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ａｋｔプロテインキナーゼ阻害剤を含む薬学的組成物 |
| WO2018035249A1 (fr) * | 2016-08-16 | 2018-02-22 | Imago Biosciences, Inc. | Compositions et procédés de production d'aminocyclopropanes stéréoisomériquement purs |
| WO2019122421A1 (fr) * | 2017-12-22 | 2019-06-27 | Astrazeneca Ab | Réduction stéréosélective de cétone à l'aide d'une enzyme cétoréductase |
| CN115843298B (zh) * | 2020-07-22 | 2024-03-29 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型 |
| WO2023043869A1 (fr) | 2021-09-15 | 2023-03-23 | Teva Pharmaceuticals International Gmbh | Formes à l'état solide de citrate d'ipatasertib |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9408197A (pt) | 1993-12-12 | 1997-08-26 | Agrogene Ltd | Método para proteger plantas contra doenças fúngicas |
| WO1998044797A1 (fr) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | Procede de traitement du cancer |
| US6201023B1 (en) | 1997-06-10 | 2001-03-13 | Agrogene Ltd. | Methods and compositions to protect crops against plant parasitic nematodes |
| WO1999023242A1 (fr) * | 1997-11-04 | 1999-05-14 | Eli Lilly And Company | Gene et proteine de cetoreductase de levure |
| EP0982300A3 (fr) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique |
| US6376496B1 (en) | 1999-03-03 | 2002-04-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU7715300A (en) | 1999-09-27 | 2001-04-30 | Merck & Co., Inc. | Method of preventing osteoporosis |
| DE10119274A1 (de) * | 2001-04-20 | 2002-10-31 | Juelich Enzyme Products Gmbh | Enzymatisches Verfahren zur enantioselektiven Reduktion von Ketoverbindungen |
| PE20050630A1 (es) | 2003-06-09 | 2005-09-22 | Boehringer Ingelheim Int | Compuestos heterociclicos como inhibidores del papiloma virus |
| PT1898903E (pt) * | 2005-06-10 | 2013-06-28 | Merck Sharp & Dohme | Inibidores da atividade de akt |
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| UA95641C2 (en) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2009036404A2 (fr) * | 2007-09-13 | 2009-03-19 | Codexis, Inc. | Polypeptides de cétoréductase pour la réduction d'acétophénones |
| EP2209775A1 (fr) | 2007-10-09 | 2010-07-28 | UCB Pharma, S.A. | Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine |
| JP5539225B2 (ja) * | 2008-01-09 | 2014-07-02 | アレイ バイオファーマ、インコーポレイテッド | Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン |
| MX2011010905A (es) | 2009-04-15 | 2011-11-01 | Abbott Lab | Compuestos antivirales. |
| AU2010310786B2 (en) | 2009-10-23 | 2014-03-27 | Eli Lilly And Company | AKT inhibitors |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| WO2012177925A1 (fr) | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3 |
| SG11201407613RA (en) | 2012-05-17 | 2015-01-29 | Array Biopharma Inc | Process for making hydroxylated cyclopentylpyrimidine compounds |
| BR112014028585B1 (pt) | 2012-05-17 | 2020-12-22 | Genentech , Inc | processo para fabricação de aminoácidos, e seus intermediários |
| PL2861582T3 (pl) | 2012-05-17 | 2016-11-30 | Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidynowych | |
| US20140121193A1 (en) | 2012-11-01 | 2014-05-01 | Robert S. Katz | Methods for treating fibromyalgia |
| JP2016513112A (ja) | 2013-02-18 | 2016-05-12 | ザ スクリプス リサーチ インスティテュート | 治療的潜在能力を有するバソプレッシン受容体のモジュレーター |
| CA2904662A1 (fr) | 2013-03-15 | 2014-09-25 | Shifa Biomedical Corporation | Composes anti-pcsk9 et methodes de traitement et/ou de prevention de maladies cardio-vasculaires |
-
2013
- 2013-05-17 MX MX2014013855A patent/MX354373B/es active IP Right Grant
- 2013-05-17 NZ NZ702950A patent/NZ702950A/en unknown
- 2013-05-17 SG SG11201407591PA patent/SG11201407591PA/en unknown
- 2013-05-17 BR BR112014028573-0A patent/BR112014028573B1/pt active IP Right Grant
- 2013-05-17 EP EP13725535.2A patent/EP2850200A1/fr active Pending
- 2013-05-17 WO PCT/US2013/041695 patent/WO2013173784A1/fr active Application Filing
- 2013-05-17 US US14/401,089 patent/US9315471B2/en active Active
- 2013-05-17 RU RU2014151014A patent/RU2642311C2/ru active
- 2013-05-17 CA CA2873661A patent/CA2873661C/fr active Active
- 2013-05-17 JP JP2015512904A patent/JP6355625B2/ja active Active
- 2013-05-17 KR KR1020147035265A patent/KR102123131B1/ko active IP Right Grant
- 2013-05-17 AU AU2013262521A patent/AU2013262521B2/en active Active
- 2013-05-17 MA MA37647A patent/MA37647A1/fr unknown
- 2013-05-17 MY MYPI2014703414A patent/MY169029A/en unknown
- 2013-05-17 CN CN201380037997.1A patent/CN104471070B/zh active Active
-
2014
- 2014-11-13 IL IL235699A patent/IL235699B/en active IP Right Grant
- 2014-12-15 ZA ZA2014/09226A patent/ZA201409226B/en unknown
-
2015
- 2015-09-16 HK HK15109047.7A patent/HK1208500A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY169029A (en) | 2019-02-04 |
| JP2015518715A (ja) | 2015-07-06 |
| EP2850200A1 (fr) | 2015-03-25 |
| HK1208500A1 (en) | 2016-03-04 |
| MX2014013855A (es) | 2016-03-21 |
| BR112014028573B1 (pt) | 2021-11-16 |
| MA37647A1 (fr) | 2016-03-31 |
| MX354373B (es) | 2018-02-28 |
| US9315471B2 (en) | 2016-04-19 |
| CA2873661A1 (fr) | 2013-11-21 |
| KR102123131B1 (ko) | 2020-06-15 |
| ZA201409226B (en) | 2017-09-27 |
| RU2014151014A (ru) | 2016-07-10 |
| BR112014028573A2 (pt) | 2018-04-24 |
| AU2013262521B2 (en) | 2017-03-02 |
| WO2013173784A1 (fr) | 2013-11-21 |
| AU2013262521A1 (en) | 2015-01-22 |
| CN104471070B (zh) | 2018-09-25 |
| CA2873661C (fr) | 2020-07-21 |
| IL235699A0 (en) | 2015-01-29 |
| RU2642311C2 (ru) | 2018-01-24 |
| IL235699B (en) | 2018-12-31 |
| NZ702950A (en) | 2016-09-30 |
| JP6355625B2 (ja) | 2018-07-11 |
| US20150099880A1 (en) | 2015-04-09 |
| KR20150018579A (ko) | 2015-02-23 |
| CN104471070A (zh) | 2015-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201403402VA (en) | Compounds | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201407613RA (en) | Process for making hydroxylated cyclopentylpyrimidine compounds | |
| SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
| SG11201407618VA (en) | Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |